Lipitas F 160mg/10mg Tablet is a combination lipid-lowering agent containing Fenofibrate 160mg and Rosuvastatin 10mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing cholesterol production and increasing LDL receptor expression. The combination therapy offers a complementary mechanism to achieve comprehensive lipid control, particularly in patients with mixed dyslipidemia who are at high cardiovascular risk. Lipitas F is indicated as an adjunct to diet and lifestyle modifications to reduce elevated LDL-C, triglycerides, and increase HDL-C levels. It is essential to monitor liver function tests and renal parameters during therapy due to potential hepatotoxicity and myopathy risks. This medication should be prescribed under medical supervision, considering contraindications such as active liver disease and hypersensitivity to either component. Patient adherence to therapy and regular lipid profile assessments are critical to optimizing therapeutic outcomes.